Quarterly ResultMay 7, 2026, 07:12 AM
Neumora Therapeutics Q1 Net Loss $53.5M; $147.1M Cash; Pipeline Updates
AI Summary
Neumora Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026, reporting a net loss of $53.5 million. The company maintained a strong financial position with $147.1 million in cash and cash equivalents, projected to support operations into the third quarter of 2027. Neumora also provided key pipeline updates, including the full enrollment of navacaprant KOASTAL-2 and -3 studies with joint topline data expected in Q2 2026, and anticipated clinical data for NMRA-511 and NMRA-898 in the second half of 2026.
Key Highlights
- Net loss for Q1 2026 was $53.5 million, compared to $68.0 million in Q1 2025.
- Cash and cash equivalents totaled $147.1 million as of March 31, 2026.
- Cash position is expected to fund operations into the third quarter of 2027.
- R&D expenses decreased to $38.6 million in Q1 2026 from $52.2 million in Q1 2025.
- G&A expenses decreased to $14.3 million in Q1 2026 from $18.8 million in Q1 2025.
- Navacaprant KOASTAL-2 and -3 studies fully enrolled; joint topline data expected in Q2 2026.
- NMRA-511 data from MAD expansion cohort in AD agitation expected in H2 2026, with Phase 2 in Q1 2027.
- NMRA-898 Phase 1 data in schizophrenia expected in the second half of 2026.